Moderna COVID-19 Vaccine
Standing Orders for Administering Vaccine to Persons 18 Years of Age and Older

<table>
<thead>
<tr>
<th>Vaccine</th>
<th>Dosage (amount)/ Route</th>
</tr>
</thead>
<tbody>
<tr>
<td>Moderna-Primary Series</td>
<td>0.5 mL/IM injection</td>
</tr>
<tr>
<td>Moderna-Booster Dose</td>
<td>0.25mL/IM injection</td>
</tr>
</tbody>
</table>

**Purpose**
- To reduce morbidity and mortality from coronavirus disease 2019 (COVID-19) by vaccinating persons who meet the criteria established by the Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices (ACIP).

**Policy**
- Where authorized under state law, standing orders enable eligible nurses and other healthcare professionals (e.g., pharmacists) to assess and vaccinate persons who meet the criteria in the "Procedure" section below without the need for clinician examination or direct order from the attending provider at the time of the interaction.

**Procedure**
Assess persons 18 years of age and older for vaccination with Moderna COVID-19 Vaccine based on the following criteria:

- **Primary-series vaccination**
  - If the recipient has never received a COVID-19 vaccine, administer 1 dose of Moderna COVID-19 Vaccine.
  - If the recipient has received 1 previous dose of Moderna COVID-19 Vaccine, administer the second dose at an interval of least 28 days.
  - If the vaccine product given as the first dose cannot be determined or is no longer available, any mRNA COVID-19 vaccine product may be administered at least 28 days after the first dose.
  - If 2 doses of an mRNA vaccine or a single dose of Janssen COVID-19 Vaccine has been administered, the person is considered fully vaccinated 2 weeks after completing the primary vaccination series.

- **Persons with a history of myocarditis or pericarditis:**
  - If history is prior to COVID-19 vaccination, may receive any FDA-authorized COVID-19 vaccine after the episode of myocarditis or pericarditis has completely resolved.
  - If myocarditis or pericarditis occurs after a dose of an mRNA vaccine, do not administer a subsequent dose of any COVID-19 vaccine. Administration of the subsequent dose of COVID-19 vaccine can be considered in certain circumstances after the episode of myocarditis or pericarditis has completely resolved. Decisions regarding vaccination should be made in consultation with the clinical team. Considerations can be found at https://www.cdc.gov/vaccines/covid-19/clinical-considerations/covid-19-vaccines-us.html#considerations-pfizer-biontech-moderna.

- **Additional primary dose for persons who are moderately or severely immune compromised†**
  - For a person aged 18 years and older who received a Moderna primary mRNA vaccine series: Administer an additional primary dose of Moderna vaccine at least 28 days after an initial 2-dose Moderna primary series. If the vaccine product cannot be determined or is no longer available, administer either mRNA COVID-19 product.

- **Persons who have received HCT or CAR-T-cell therapy**
  - Revaccinate persons who received doses of COVID-19 vaccine prior to receiving HCT or CAR-T-cell therapy with a primary series at least 3 months (12 weeks) after transplant or CAR-T-cell therapy.

- **Booster doses**
  - Administer a booster dose, at least 5 months after the last dose of a COVID-19 mRNA vaccine primary series (i.e., the 2nd dose or additional primary series dose for moderately or severely immunocompromised persons) to persons 18 years of age and older.
  - Persons vaccinated with a Janssen COVID-19 Vaccine: Administer a booster dose at least 2 months after completing the single-dose primary series.
  - Use of heterologous booster doses is allowed; however, mRNA COVID-19 vaccines are preferred.
  - For additional information, see Interim Clinical Considerations for Use of COVID-19 Vaccines Currently Approved or Authorized in the United States https://www.cdc.gov/vaccines/covid-19/clinical-considerations/covid-19-vaccines-us.html#booster-dose

- **Additional Clinical Considerations**
  - For persons who received a COVID-19 vaccine:
    - Outside of the United States
    - Not currently authorized/approved in the United States
  - See clinical guidance, including booster dose recommendations, at https://www.cdc.gov/vaccines/

† For a list of conditions associated with moderate to severe immune compromise, see: https://www.cdc.gov/vaccines/covid-19/clinical-considerations/covid-19-vaccines-us.html#considerations-covid19-vax-immunocompromised
Moderna COVID-19 Vaccine
Standing Orders for Administering Vaccine to Persons 18 Years of Age and Older

- Moderna COVID-19 vaccine may be coadministered with other vaccines without regard to timing, including simultaneous administration.

### Screen for Contraindications and Precautions

#### Contraindications:

- History of a:
  - Severe allergic reaction (e.g., anaphylaxis) after a previous dose or to a component of the COVID-19 vaccine
  - Known diagnosed allergy to a component of the COVID-19 vaccine (see [https://www.cdc.gov/vaccines/covid-19/clinical-considerations/covid-19-vaccines-us.html#Appendix-C](https://www.cdc.gov/vaccines/covid-19/clinical-considerations/covid-19-vaccines-us.html#Appendix-C) for a list of vaccine components)

- Immediate allergic reaction‡ to any non-COVID-19 vaccine or injectable therapy (i.e., intramuscular, intravenous, or subcutaneous vaccines or therapies [excluding subcutaneous immunotherapy for allergies, i.e., “allergy shots”])
  - This includes non-COVID-19 vaccines and therapies with multiple components and the component(s) that elicited the reaction is unknown
- Immediate (within 4 hours after vaccination) non-severe, allergic reaction to a previous dose of the COVID-19 vaccine
- Contraindication to one type of COVID-19 vaccine (mRNA)§ is a precaution to other types of COVID-19 vaccines (Janssen)
  - Moderate to severe acute illness

### Precautions:

- Most people determined to have a precaution to a COVID-19 vaccine at their appointment can and should be administered vaccine.
- Contraindication to Janssen COVID-19 Vaccine (including due to a known polysorbate allergy) has a precaution to mRNA COVID-19 vaccination.
  - People with a contraindication to mRNA COVID-19 vaccines (including due to a known PEG allergy) have a precaution to Janssen COVID-19 vaccination.
  - People who have previously received an mRNA COVID-19 vaccine dose should wait at least 28 days to receive Janssen COVID-19 Vaccine.

### Needle Gauge, Needle Length, Injection Site

<table>
<thead>
<tr>
<th>Sex and Weight of Patient</th>
<th>Needle Gauge</th>
<th>Needle Length</th>
<th>Injection Site</th>
</tr>
</thead>
<tbody>
<tr>
<td>Female or male fewer than 130 lbs</td>
<td>22–25</td>
<td>¾” – 1”</td>
<td>Deltoid muscle of arm</td>
</tr>
<tr>
<td>Female or male 130–152 lbs</td>
<td>22–25</td>
<td>1”</td>
<td>Deltoid muscle of arm</td>
</tr>
<tr>
<td>Female 152–200 lbs</td>
<td>22–25</td>
<td>1–1½”</td>
<td>Deltoid muscle of arm</td>
</tr>
<tr>
<td>Male 152–260 lbs</td>
<td>22–25</td>
<td>1–1½”</td>
<td>Deltoid muscle of arm</td>
</tr>
<tr>
<td>Female 200+ lbs</td>
<td>22–25</td>
<td>1½”</td>
<td>Deltoid muscle of arm</td>
</tr>
<tr>
<td>Male 260+ lbs</td>
<td>22–25</td>
<td>1½”</td>
<td>Deltoid muscle of arm</td>
</tr>
</tbody>
</table>

### Administer Moderna COVID-19 Vaccine by intramuscular (IM) injection

- 0.5 mL for primary series and additional primary dose (moderately to severely immunocompromised persons)
- 0.25 mL for booster dose

### Document vaccination

- COVID-19 vaccination providers must document vaccine administration in their medical record systems within 24 hours of administration and use their best efforts to report administration data to the relevant system (e.g., immunization information system) for the jurisdiction as soon as practicable and no later than 72 hours after administration.

---

‡ An immediate allergic reaction is defined as any hypersensitivity-related signs or symptoms such as urticaria, angioedema, respiratory distress (e.g., wheezing, stridor), or anaphylaxis that occur within 4 hours following exposure to a vaccine or medication.

§ Consider consultation with an allergist-immunologist to help determine if a patient with a contraindication to an mRNA vaccine can safely receive the Janssen COVID-19 Vaccine. Healthcare providers and health departments may also request a consultation from the Clinical Immunization Safety Assessment COVIDvax project ([https://www.cdc.gov/vaccinesafety/ensuringsafety/monitoring/cisa/index.html](https://www.cdc.gov/vaccinesafety/ensuringsafety/monitoring/cisa/index.html)). Vaccination of these individuals should only be done in an appropriate setting under the supervision of a healthcare provider experienced in the management of severe allergic reactions.

** Some experts recommend a 5/8-inch needle for men and women who weigh less 130 pounds. If used, skin must be stretched tightly (do not bunch subcutaneous tissue).
Document each recipient’s vaccine administration information:
- Medical record: The vaccine and the date it was administered, manufacturer, lot number, vaccination site and route, name and title of the person administering the vaccine
- Vaccination record card: Date of vaccination, product name/manufacturer, lot number, and name/location of the administering clinic or healthcare professional. Give to the vaccine recipient.
- Immunization information system (IIS): Report the vaccination to the appropriate state/local IIS.

Additional preparation and administration information including booster dose information is available on the manufacturer’s website at https://www.modernatx.com/.

Be prepared to manage medical emergencies.
- Vaccination providers should observe patients after vaccination to monitor for the occurrence of immediate adverse reactions, including syncope:
  - 30 minutes: persons with a history of:
    - A contraindication to another type of COVID-19 vaccine product.
    - Immediate (within 4 hours of exposure) non-severe allergic reaction to a COVID-19 vaccine.
    - Immediate allergic reaction of any severity to a non-COVID-19 vaccine or injectable therapies
    - Anaphylaxis due to any cause.
  - 15 minutes: All other persons
- Syncope may occur in association with injectable vaccines, in particular among adolescents. Procedures should be in place to avoid falling injuries and manage syncopal reactions.
- Have a written protocol to manage medical emergencies following vaccination, as well as equipment and medications, including at least 3 doses of epinephrine, H1 antihistamine, blood pressure monitor, and timing device to assess pulse.
- Healthcare personnel who are trained and qualified to recognize the signs and symptoms of anaphylaxis as well as administer intramuscular epinephrine should be available at the vaccination location at all times.

For more information, please see:
- CDC’s General Best Practice Guidelines for Immunization, “Preventing and Managing Adverse Reactions,” at https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/adverse-reactions.html
- Immunization Action Coalition’s “Medical Management of Vaccine Reactions in Adults in a Community Setting” at https://www.immunize.org/catg.d/p3082.pdf

Report adverse events to the Vaccine Adverse Event Reporting System (VAERS).
- While this vaccine is under Emergency Use Authorization (EUA), (https://www.fda.gov/emergency-preparedness-and-response/mcm-legal-regulatory-and-policy-framework/emergency-use-authorization) healthcare professionals are required to report to VAERS:
  - Vaccine administration errors (whether associated with an adverse event [AE] or not)
  - Serious AEs (irrespective of attribution to vaccination)
  - Cases of COVID-19 that result in hospitalization or death
  - Any additional AEs and revised safety requirements per the Food and Drug Administration’s (https://www.fda.gov/emergency-preparedness-and-response/mcm-legal-regulatory-and-policy-framework/emergency-use-authorization) conditions for use of an authorized vaccine throughout the duration of the EUA
- Healthcare professionals are encouraged to report to VAERS:
  - Clinically important adverse events that occur after vaccination, even if you are not sure whether the vaccine caused the adverse event

Note: For more information/guidance, please contact the immunization program at your state or local health department or the appropriate state body (e.g., state board of medical/nursing/pharmacy practice).

Standing Orders Authorization

This policy and procedure shall remain in effect for all patients of the ____________________________
effective ___________________________ until rescinded or until ___________________________.

Medical director (or other authorized practitioner)
____________________________________ / ______________________________________ / ________________.

Adapted with appreciation from the Immunization Action Coalition (IAC) standing orders